Use Vitamin D3 and K2 This Way to Heal Your Arteries After 60

The most popular D3-and-K2 combination pill on the market has a math problem: to reach an effective K2 dose, you'd need to take a D3 dose most clinicians wouldn't recommend without monitoring. This video walks through the actual research behind both nutrients — a landmark study linking low vitamin D to heart attack risk, why the VITAL trial didn't settle the question the way headlines suggested, and two real coronary calcium trials that reveal K2's benefit may work upstream, on metabolic health, rather than directly on your arteries. Sources: Giovannucci et al., Archives of Internal Medicine 2008; Manson et al. (VITAL), NEJM 2019; VitaK-CAC study, JAMA Cardiology 2024; Rahimi Sakak et al., European Journal of Nutrition 2021. Educational content only, not medical advice — talk to your doctor before starting or adjusting either supplement, especially if you're on a blood thinner. Tags: vitamin D3, vitamin K2, MK-7, coronary artery calcium, matrix Gla protein, insulin resistance, heart health, supplement dosing, arterial plaque, metabolic health DISCLAIMER This video is for educational purposes only and isn't medical advice. Vitamin D and K2 dosing should be guided by your own bloodwork and a physician familiar with your history — this is especially important if you take warfarin or another anticoagulant, have kidney disease, or have a condition affecting calcium metabolism. Talk to your doctor before starting or adjusting either supplement. SOURCES REFERENCED 25-Hydroxyvitamin D and Risk of Myocardial Infarction in Men: A Prospective Study. Giovannucci E, et al. Archives of Internal Medicine, 2008;168(11):1174–1180. Health Professionals Follow-up Study; men with 25(OH)D below 15 ng/mL had roughly 2.4 times the risk of myocardial infarction compared with those at 30 ng/mL or above, with elevated risk persisting even in the 22.6–29.9 ng/mL range. Vitamin D Supplements and Prevention of Cardiovascular Disease and Cancer. Manson JE, et al. (VITAL trial). New England Journal of Medicine, 2019;380(1):33–44. 25,871 participants, fixed 2,000 IU/day D3 dose versus placebo, median 5.3 years; no significant reduction in major cardiovascular events, without baseline vitamin D level stratification. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial (VitaK-CAC study). JAMA Cardiology, 2024. 180 patients with existing coronary artery disease; 360 mcg/day MK-7 versus placebo over 2 years; CAC score progression 135→184 (MK-7) versus 145→214 (placebo), roughly 29% less progression. Glycemic Control Improvement in Individuals with Type 2 Diabetes with Vitamin K2 Supplementation. Rahimi Sakak F, et al. European Journal of Nutrition, 2021;60(5):2495–2506. 68 patients with T2DM, 360 mcg/day MK-7 for 12 weeks; significant improvements in fasting plasma glucose and HbA1c versus placebo. A related secondary analysis of insulin-resistance indexes in the same cohort found a more mixed result after adjusting for baseline values. Trial data on aortic valve calcification and higher-dose MK-7 (720 mcg/day) reflect published research on vitamin K2 and vascular calcification in older adults with existing calcification; specific supporting citation available on request if needed for the description.